NCT00717925View on ClinicalTrials.gov

Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Lymphoma, B-Cell
Interventions
DRUG

Inotuzumab Ozogamicin (CMC-544)

Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00717925 - Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) | Biotech Hunter | Biotech Hunter